Evidence map›Paper›PMID 26858516›Full record

ArticleMediators of inflammation2015

Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated by Escherichia coli O104:H4.

Alexander Lukasz, Jan Beneke, Kristina Thamm, Jan T Kielstein, Jan Menne, Jan-Henrik Mikesch, Bernhard M W Schmidt, Hermann Haller, Philipp Kümpers, Sascha David and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Angiopoietin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
    Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Alexander LukaszDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany; Department of Medicine, Division of General Internal Medicine, Nephrology, and Rheumatology, University Hospital Münster, Albert-Schweitzer-Strasse 33, 48149 Münster, Germany.
Jan BenekeDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Kristina ThammDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Jan T KielsteinDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Jan MenneDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Jan-Henrik MikeschDepartment of Hematology, Hemostaseology, Oncology and Pneumonology, University Hospital Münster, Albert-Schweitzer-Strasse 33, 48149 Münster, Germany.
Bernhard M W SchmidtDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Hermann HallerDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Philipp KümpersDepartment of Medicine, Division of General Internal Medicine, Nephrology, and Rheumatology, University Hospital Münster, Albert-Schweitzer-Strasse 33, 48149 Münster, Germany.
Sascha DavidDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Mario SchifferDepartment of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany.
Medizinische Hochschule Hannover · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escherichia coli O104:H4-associated hemolytic uremic syndrome (HUS) is characterized by Shiga toxin-induced vascular damage. As indicated by recent studies, dysregulation of the angiopoietin (Angpt)/Tie2 ligand receptor system may be crucial for endothelial dysfunction in HUS. Early Angpt-2 levels quantified in 48 adult HUS patients were predictive for a complicated clinical course, in particular for need of hemodialysis and mechanical ventilation as well as occurrence of seizures. In vitro challenge of human umbilical vein endothelial cells with patients' sera indicated an injurious mediator role of Angpt-2 opening future perspectives for mitigating endothelial activation in HUS.

Indexed as

Shiga-Toxigenic Escherichia coliAdultAngiopoietin-2Cohort StudiesEndothelium, VascularFemaleHemolytic-Uremic SyndromeHumansMaleMiddle AgedPhosphorylationReceptor, TIE-2Angiopoietin-2ANGPT2 protein, humanReceptor, TIE-2

Identifiers

PMID26858516
PMCPMC4706916
OpenAlexW2273337074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.